<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117465</article-id><article-id pub-id-type="publisher-id">ACM-44144</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_96801460.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  利妥昔单抗在儿童原发性肾病综合征的应用新进展
  New Progress in the Application of Rituximab in Children with Primary Nephrotic Syndrome
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>建</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>颜</surname><given-names>嘉葳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>运广</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>右江民族医学院研究生院，广西 百色</addr-line></aff><aff id="aff3"><addr-line>右江民族医学院附属医院，广西 百色</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3203</fpage><lpage>3208</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  原发性肾病综合征(Primary nephrotic syndrome, PNS)是儿童最常见的肾小球疾病，其发病与自身免疫有关，约25%的患者表现为频复发或激素依赖、激素耐药，进而发展成难治性肾病综合征，以单独的糖皮质激素或联合免疫抑制剂治疗为主。利妥昔单抗(rituximab，RTX)是一种诱导B细胞溶解和凋亡的嵌合抗CD20单克隆抗体，能够预防或延缓儿童原发性肾病综合征患者的复发，延缓进入终末期肾病。近年来，已有多个病例回顾性研究和随机对照试验证实利妥昔单抗在治疗原发性肾病综合的有效性和安全性，极大的改善了儿童原发性肾病综合征的预后。本文就RTX的作用机制、在儿童PNS临床应用疗效及不良反应进行综述。
   Primary nephrotic syndrome (PNS) is the most common glomerular disease in children. Its onset is related to autoimmunity. Approximately 25% of patients show frequent relapses or hormone dependence and hormone resistance, and then develop into refractory nephrotic syndrome which is mainly treated with glucocorticoid alone or combined with immunosuppressive agents. Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that induces B cell lysis and apoptosis. It can prevent or delay the recurrence of children with primary nephrotic syndrome and delay the entry into end-stage renal disease. In recent years, retrospective studies and randomized controlled trials of multiple cases have confirmed the effectiveness and safety of rituximab in the treatment of primary nephrotic syndrome, which has greatly improved the prognosis of children with primary nephrotic syndrome. This article reviews the mechanism of action of RTX, its clinical efficacy and adverse reactions in Children PNS.
 
</p></abstract><kwd-group><kwd>肾病综合征，儿童，利妥昔单抗，治疗, Nephrotic Syndrome</kwd><kwd> Children</kwd><kwd> Rituximab</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>原发性肾病综合征(Primary nephrotic syndrome, PNS)是儿童最常见的肾小球疾病，其发病与自身免疫有关，约25%的患者表现为频复发或激素依赖、激素耐药，进而发展成难治性肾病综合征，以单独的糖皮质激素或联合免疫抑制剂治疗为主。利妥昔单抗(rituximab，RTX)是一种诱导B细胞溶解和凋亡的嵌合抗CD20单克隆抗体，能够预防或延缓儿童原发性肾病综合征患者的复发，延缓进入终末期肾病。近年来，已有多个病例回顾性研究和随机对照试验证实利妥昔单抗在治疗原发性肾病综合的有效性和安全性，极大的改善了儿童原发性肾病综合征的预后。本文就RTX的作用机制、在儿童PNS临床应用疗效及不良反应进行综述。</p></sec><sec id="s2"><title>关键词</title><p>肾病综合征，儿童，利妥昔单抗，治疗</p></sec><sec id="s3"><title>New Progress in the Application of Rituximab in Children with Primary Nephrotic Syndrome<sup> </sup></title><p>Jian Li<sup>1</sup>, Jiawei Yan<sup>1</sup>, Yunguang Liu<sup>2*</sup></p><p><sup>1</sup>Graduate School of Youjiang Medical College for Nationalities, Baise Guangxi</p><p><sup>2</sup>Affiliated Hospital of Youjiang Medical College for Nationalities, Baise Guangxi</p><p><img src="//html.hanspub.org/file/46-1572425x4_hanspub.png?20210727090259182" /></p><p>Received: Jun. 21<sup>st</sup>, 2021; accepted: Jul. 11<sup>th</sup>, 2021; published: Jul. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/46-1572425x6_hanspub.png?20210727090259182" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Primary nephrotic syndrome (PNS) is the most common glomerular disease in children. Its onset is related to autoimmunity. Approximately 25% of patients show frequent relapses or hormone dependence and hormone resistance, and then develop into refractory nephrotic syndrome which is mainly treated with glucocorticoid alone or combined with immunosuppressive agents. Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that induces B cell lysis and apoptosis. It can prevent or delay the recurrence of children with primary nephrotic syndrome and delay the entry into end-stage renal disease. In recent years, retrospective studies and randomized controlled trials of multiple cases have confirmed the effectiveness and safety of rituximab in the treatment of primary nephrotic syndrome, which has greatly improved the prognosis of children with primary nephrotic syndrome. This article reviews the mechanism of action of RTX, its clinical efficacy and adverse reactions in Children PNS.</p><p>Keywords:Nephrotic Syndrome, Children, Rituximab, Treatment</p><disp-formula id="hanspub.44144-formula22"><graphic xlink:href="//html.hanspub.org/file/46-1572425x7_hanspub.png?20210727090259182"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/46-1572425x8_hanspub.png?20210727090259182" /> <img src="//html.hanspub.org/file/46-1572425x9_hanspub.png?20210727090259182" /></p></sec><sec id="s5"><title>1. 引言</title><p>原发性肾病综合征(PNS)是小儿最常见的泌尿系统疾病之一，原发于肾小球，以大量蛋白尿、低白蛋白血症、伴或不伴有水肿和高脂血症为临床表现的综合征，大约每10万名1~18岁的儿童中就有5名患病，不同种族之间存在显著差异 [<xref ref-type="bibr" rid="hanspub.44144-ref1">1</xref>]。PNS的发病机制尚不是十分明确，已经提出了基因突变、T和B淋巴细胞、全身循环因子(CPfS)以及足细胞和内皮细胞之间的旁分泌的参与 [<xref ref-type="bibr" rid="hanspub.44144-ref2">2</xref>]。从20世纪50年代开始，国内外学者都认为糖皮质激素是被用来治疗PNS的首选药物。临床上根据PNS对激素治疗的敏感性，已经将PNS 分为激素敏感型肾病综合征(steroid-sensitive nephrotic syndrome, SSNS)、激素抵抗型肾病综合征(steroid-resistant nephrotic syndrome, SRNS)，在SSNS患儿中，由于50%以上的患者表现为频繁复发型肾病综合征(frequently relapsing nephrotic syndrome, FRNS)或激素依赖型肾病综合征(steroid-dependent nephritic syndrome, SDNS)，则SRNS、FRNS及SDNS一起被大家称为原发性难治性肾病综合征(idiopathic refractory nephritic syndrome, IRNS)，又由于IRNS常导致儿童终末期肾病，所以IRNS在临床上对于我们医生来说是一个比较难处理的问题。IRNS患儿通常需要服用大量糖皮质激素或者各种免疫抑制剂，如他克莫司、环孢素A、环磷酰胺和霉酚酸酯才能控制病情，一些患儿可能需要多靶点治疗，如联合类固醇激素、霉酚酸酯和钙调神经磷酸酶抑制剂(calcineurin inhibitors, CNIs)一起治疗，在过去10多年，已有许多研究报道利妥昔单抗在治疗复杂FRNS/SDNS和难治性SRNS有效性，成功地延缓肾病综合征向终末期肾病发展 [<xref ref-type="bibr" rid="hanspub.44144-ref3">3</xref>]。近年来，国内外关于RTX治疗FRNS/SDNS和SRNS显著疗效引起了研究者的广泛关注，RTX在患有各种肾脏疾病的儿童和成人中表现出显著的疗效。本文就RTX治疗儿童PNS的机制、临床应用疗效、不良反应等方面进行综述。</p></sec><sec id="s6"><title>2. RTX治疗PNS的作用机制</title><p>RTX是由鼠抗CD20单克隆抗体2B8的轻链可变区和重链可变区与人K轻链和Υ1重链恒定区结合而成的一种嵌合鼠源性单克隆抗体，能够识别和表达于B细胞表明的CD20分子，使钙通道打开，通过信号转导途径和多种激酶级联反应的作用，诱导B细胞凋亡 [<xref ref-type="bibr" rid="hanspub.44144-ref4">4</xref>]。CD20是大多数人类B淋巴细胞表达的抗原，由于RTX与CD20巧妙的特异性结合从而可抑制CD20介导的B细胞增殖和分化，最初该药物用于治疗非霍奇金淋巴瘤患者治疗循环抗体诱发的肾小球疾病，如特发性膜性肾病和抗中性粒细胞胞浆抗体相关血管炎 [<xref ref-type="bibr" rid="hanspub.44144-ref5">5</xref>]。研究 [<xref ref-type="bibr" rid="hanspub.44144-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.44144-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.44144-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.44144-ref9">9</xref>] 提示，B细胞能够使T细胞活化，通过介导抗体非依赖性自身免疫损伤，并提供共刺激分子和细胞因子，在自身免疫性疾病中维持T细胞的激活。有研究 [<xref ref-type="bibr" rid="hanspub.44144-ref10">10</xref>] 表明利妥昔单抗可抑制B细胞增殖并诱导B细胞凋亡，抑制B细胞与T细胞之间的相互作用，从而防止肾病综合征的复发。研究发现 [<xref ref-type="bibr" rid="hanspub.44144-ref11">11</xref>]，RTX可诱导调节性T细胞数量、功能增加以及功能恢复。另外研究 [<xref ref-type="bibr" rid="hanspub.44144-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.44144-ref13">13</xref>] 发现，RTX通过足细胞表面的鞘磷脂磷酸二酯酶类3b (Acid Sphingomyelinase-like Phosphodiesterase 3b, SMPDL-3b)结合，调节酸性髓磷脂酶(acid Sphinggomyelinase, ASMase)的活性，抑制足细胞的凋亡以及防止肌动蛋白细胞骨架被破坏，同时RTX通过介导SMPDL-3b/ASM信号转导通路，调节ASM的Th17细胞抑制IL-17的产生，从而抑制炎症反应对足细胞的损伤，同时在肾移植时用RTX治疗局灶性节段性肾小球硬化(Focal segmental glomerulosclerosis, FSGS)患者时，似乎是通过SMPDL-3b-120信号转导方式调节足细胞功能来防止FSGS复发。总之，RTX可通过细胞免疫学机制及通过信号转导直接作用于足细胞的情况下，延缓肾病综合征的复发。</p></sec><sec id="s7"><title>3. RTX在FRNS/SDNS患儿中的临床应用</title><p>在2012年，RTX被专家们列入改善全球肾病预后组织(KDIGO)指南，而且提出RTX能够用于激素和免疫抑制方案治疗后仍有频繁复发患儿，或对其他免疫抑制剂治疗有明显不良反应的患儿。Lijima [<xref ref-type="bibr" rid="hanspub.44144-ref14">14</xref>] 等人在一项多中心、双盲、随机、安慰剂对照试验提示，24例患儿RTX组[375 mg/(m<sup>2</sup>&#183;次)，每周一次，最大500 mg/m<sup>2</sup>，持续4周]的中位无复发期为267天，明显长于24例安慰剂组的101天，RTX组复发率及1年内所需的皮质类固醇量明显低于安慰剂组。在这项纵向的患者内对照研究中 [<xref ref-type="bibr" rid="hanspub.44144-ref15">15</xref>] 发现抗CD20mAb RTX明显降低了10名儿童和20名成人SDNS或FRNS患者的复发频率，结果提示安全有效，同时在一年的观察期内，使用RTX的复发率比在RTX治疗前一年的复发率降低了约3倍左右，而且在18名从未接受任何治疗的患者身上，他们在使用RTX治疗后，肾病综合征再未复发。Van Horebeek [<xref ref-type="bibr" rid="hanspub.44144-ref16">16</xref>] 等在回顾性研究中报道的9例SDNS患儿，在接受RTX治疗[375 mg/(m<sup>2</sup>&#183;次)，每周一次，1~5次]，B细胞耗竭中位数从2.75年，恢复时间230天，在停止或减少免疫抑制治疗的剂量的情况下，年复发率由1.70降低至0.26，而且在没有严重不良事件的情况下，明显降低每年的复发率，并有助于减少其他免疫抑制剂药物的使用率。Basu等 [<xref ref-type="bibr" rid="hanspub.44144-ref17">17</xref>] 在RTX与他克莫司治疗SDNS的前瞻性随机对照临床试验表明176例儿童接受为期12个月的他克莫司联合强的松龙治疗或单疗程的RTX [单次输注两剂375 mg/(m<sup>2</sup>&#183;次)]，RTX治疗的12个月无复发生存率为90.0%，高于他克莫司无复发生存率的63.3%；同时表明，在患有SDNS的儿童中，初次使用利妥昔单抗可显著降低复发率，且在12月内维持SDNS的缓解的时间和最大限度地降低皮质类固醇激素的使用率比他克莫司更好。综上所述，RTX治疗FRNS/SDNS是安全有效的，可以维持缓解，同时能够减少皮质类固醇激素和免疫抑制剂的用量，加快B细胞耗竭从而显著降低复发率，延长缓解期。</p></sec><sec id="s8"><title>4. RTX在SRNS患儿中的临床应用</title><p>Bagga [<xref ref-type="bibr" rid="hanspub.44144-ref18">18</xref>] 等首次报道RTX治疗5名难治性SRNS儿童，年龄为2.8~16.0岁，在接受RTX治疗后[375 mg/(m<sup>2</sup>&#183;次)，每周一次，持续4周]，4例完全缓解，1例部分缓解，提示RTX治疗效果良好。Sinha [<xref ref-type="bibr" rid="hanspub.44144-ref19">19</xref>] 等人均给4次同种剂量的RTX治疗的33例SRNS患儿，研究表明在最后一次予RTX治疗后的6个月内，9例患儿得到了完全缓解，7例得到了部分缓解，17例患儿在RTX治疗后无反应。然而Kamei [<xref ref-type="bibr" rid="hanspub.44144-ref20">20</xref>] 等描述了10名难治性SRNS患儿联合使用RTX、甲基泼尼松龙(MPT)和免疫抑制剂治疗后，其中6名患者接受了单剂RTX治疗，2名患者接受了两剂RTX治疗，2名患者接受了4剂RTX治疗，结果显示，7例完全缓解，1例部分缓解，2例无反应，而且有7例SRNS患儿在随访中，肾功能一直表现正常且无蛋白尿。Hosein [<xref ref-type="bibr" rid="hanspub.44144-ref21">21</xref>] 和他的同事设计一项研究，评估RTX治疗激素和环孢素耐药与SDNS和环孢素依赖儿童的疗效和安全性，在他们对43名对类固醇激素和环孢素耐药或SDNS和环孢素依赖的非先天性肾病综合征的儿童进行了利妥昔单抗静脉注射治疗(375 mg/m<sup>2</sup>/wk，共4周)，结果表明在患有SDNS和环孢素耐药的肾病综合征的23名患儿，8名完全缓解，3名部分缓解。Suyama等 [<xref ref-type="bibr" rid="hanspub.44144-ref22">22</xref>] 在利妥昔单抗联合小剂量环孢素(RTX-Cyat)治疗5例激素耐药FSGS患儿的研究中表明，在2次RTX-Cyat治疗情况下，所有SRNS的FSGS患儿都得完全缓解，且所有患者在RTX-Cyat治疗3个月后停用强的松龙(PSL)治疗，同时在RTX-Cyat治疗后1个月，CD19阳性细胞数均降至&lt;1%，所有患者都处于缓解期，缓解时间都维持在259.6 &#177; 68.2 d左右。综上所述，RTX对儿童SRNS有一定疗效，增加RTX治疗次数或RTX联合多靶点治疗，如MPT、PSL和免疫抑制剂，可能比单独利妥昔单抗更有效，由于以上样本量小，但仍需要进行大规模、多中心的前瞻性研究来评估这些方案的有效性和安全性。</p></sec><sec id="s9"><title>5. RTX治疗儿童PNS的不良反应</title><p>RTX在儿童PNS治疗中，其安全性和耐受性是良好的，最常见的不良反应为输液反应，如腹痛、发热、呕吐、腹泻、支气管痉挛、皮疹、心动过速和高血压 [<xref ref-type="bibr" rid="hanspub.44144-ref23">23</xref>]，由于输液反应通常在24小时内被发现，且症状轻，一般都可以通过减慢输液速度、暂停输液、使用类固醇激素及抗组胺药而得到缓解。Sun [<xref ref-type="bibr" rid="hanspub.44144-ref24">24</xref>] 等人在RTX治疗12名IRNS期间，3名患者出现皮疹，1名患者出现低血压，1名患者出现发烧，在降低滴速或使用类固醇后，这些不良反应很快就消失了。Bonanni等 [<xref ref-type="bibr" rid="hanspub.44144-ref25">25</xref>] 人报道RTX治疗儿童PNS时，其早发和晚发的不良反应有中性粒细胞减少、关节炎、肺炎、感染以及RTX所致的肺相关肺损伤。Parmentier [<xref ref-type="bibr" rid="hanspub.44144-ref26">26</xref>] 等的前瞻性研究报道了RTX在治疗107例SDNS患儿中，有26例患儿出现低丙种球蛋白血症并发症，又有13例患儿同时出现感染，包括5例肺炎，1例暴发性病毒性心肌炎，1例病毒性脑膜炎，4例耳鼻喉炎，1例水痘和1例EBV感染。与Fujinaga [<xref ref-type="bibr" rid="hanspub.44144-ref27">27</xref>] 等人最近的一份研究，6名儿童中分别有2名和4名患者出现严重的中性粒细胞减少症和低丙种球蛋白血症的结论相似。RTX治疗儿童肾病综合征其它严重的不良反应，肺孢子虫肺炎 [<xref ref-type="bibr" rid="hanspub.44144-ref28">28</xref>]、免疫介导的溃疡性结肠炎 [<xref ref-type="bibr" rid="hanspub.44144-ref29">29</xref>]、肺纤维化 [<xref ref-type="bibr" rid="hanspub.44144-ref30">30</xref>]、致命的肺损伤综合征 [<xref ref-type="bibr" rid="hanspub.44144-ref31">31</xref>] 等并发症。RTX的使用会产生不同的副作用，这些副作用的频率和严重程度是否取决于CD20抗体的药理学特性，还是取决于使用这些药物治疗的疾病的复杂性，仍需要我们在未来研究中去探究。</p></sec><sec id="s10"><title>6. 总结与展望</title><p>RTX是诱导或延长PNS儿童临床缓解的一种有效的且未来前景好的治疗选择，并且RTX可以通过多种作用机制很好地发挥其临床治疗作用，这样可以有效缓解我们临床儿科医师和PNS患儿的治疗压力。现在有越来越多的证据表明，在患有SDNS、FRNS及SRNS的儿童中，RTX能在诱导长期缓解、减少皮质类固醇激素使用和副作用方面表现出有效性和安全性。RTX在治疗儿童PNS的疗效不同，是否与种族、RTX治疗方案、伴随治疗、RTX治疗时间、病理类型、地域差异及患儿本身异质性有关，仍需要多中心、前瞻性、大样本、长时间的临床随机和对照实验来证实。</p><p>有关未来重点研究方向有以下方面：(1) 为儿童PNS建立更有效的RTX给药方案，关于RTX治疗PNS标准剂量、疗程及联合多靶点给药方案，并确定对不同病理类型的PNS最合适的给药方案而确定有效性和安全性。(2) 测定缓解期和复发期PNS患儿的RTX药代动力学和药效学，因为这方面的研究目前尚未在儿童中有过充分的研究。(3) 建立生物标志物，预测儿童PNS患者对利妥昔单抗的长期反应，可以在复发时与生物标志物恢复时，在最佳时机内，通过再次给药从而达到PNS的持续缓解，并将多靶点药物使用频率降至最低。</p></sec><sec id="s11"><title>文章引用</title><p>李 建,颜嘉葳,刘运广. 利妥昔单抗在儿童原发性肾病综合征的应用新进展New Progress in the Application of Rituximab in Children with Primary Nephrotic Syndrome[J]. 临床医学进展, 2021, 11(07): 3203-3208. https://doi.org/10.12677/ACM.2021.117465</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44144-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bertelli, R., Bonanni, A., Di, D.A., et al. (2016) Regulatory T Cells and Minimal Change Nephropathy: In the Midst of a Complex Network. Clinical &amp; Experimental Immunology, 183, 166-174. &lt;br&gt;https://doi.org/10.1111/cei.12675</mixed-citation></ref><ref id="hanspub.44144-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Noone, D., Iijima, K. and Parekh, R. (2018) Idiopathic Nephrotic Syndrome in Children. The Lancet (London, England), 392, 61-74. &lt;br&gt;https://doi.org/10.1016/S0140-6736(18)30536-1</mixed-citation></ref><ref id="hanspub.44144-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Kamei, K., et al. (2020) Rituximab Therapy for Refractory Steroid-Resistant Nephrotic Syndrome in Children. Pediatric Nephrology, 35, 17-24. &lt;br&gt;https://doi.org/10.1007/s00467-018-4166-1</mixed-citation></ref><ref id="hanspub.44144-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Iijima, K., Sako, M., Kamei, K. and Nozu, K. (2018) Rituximab in Steroid-Sensitive Nephrotic Syndrome: Lessons from Clinical Trials. Pediatric Nephrology, 33, 1449-1455. &lt;br&gt;https://doi.org/10.1007/s00467-017-3746-9</mixed-citation></ref><ref id="hanspub.44144-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Iijima, K., Sako, M. and Nozu, K. (2017) Rituximab for Nephrotic Syndrome in Children. Clinical and Experimental Nephrology, 21, 193-202. &lt;br&gt;https://doi.org/10.1007/s10157-016-1313-5</mixed-citation></ref><ref id="hanspub.44144-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Liu, K. and Mohan, C. (2009) Altered B-Cell Signaling in Lupus. Autoimmunity Reviews, 8, 214-218.  
&lt;br&gt;https://doi.org/10.1016/j.autrev.2008.07.048</mixed-citation></ref><ref id="hanspub.44144-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chan, O.T., Hannum, L.G., Haberman, A.M., Madaio, M.P. and Shlomchik, M.J. (1999) A Novel Mouse with B Cells But Lacking Serum Antibody Reveals an Antibody-Independent Role for B Cells in Murine Lupus. Journal of Experimental Medicine, 189, 1639-1648. &lt;br&gt;https://doi.org/10.1084/jem.189.10.1639</mixed-citation></ref><ref id="hanspub.44144-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Sfi kakis, P.P., Boletis, J.N., Lionaki, S., et al. (2005) Remission of Proliferative Lupus Nephritis Following B Cell Depletion Therapy Is Preceded by Down-Regulation of the T Cell Costimulatory Molecule CD40 Ligand: An Open-Label Trial. Arthritis &amp; Rheumatology, 52, 501-513. &lt;br&gt;https://doi.org/10.1002/art.20858</mixed-citation></ref><ref id="hanspub.44144-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bugatti, S., Codullo, V., Caporali, R. and Montecucco, C. (2007) B Cells in Rheumatoid Arthritis. Autoimmunity Reviews, 7, 137-142. &lt;br&gt;https://doi.org/10.1016/j.autrev.2007.02.017</mixed-citation></ref><ref id="hanspub.44144-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Maloney, D.G. (2001) Mechanism of Action of Rituximab. Anticancer Drugs, 12, S1-S4.</mixed-citation></ref><ref id="hanspub.44144-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Stasi, R., Cooper, N., Del Poeta, G., et al. (2008) Analysis of Regulatory T-Cell Changes in Patients with Idiopathic Thrombocytopenic Purpura Receiving B Cell-Depleting Therapy with Rituximab. Blood, 112, 1147-1150.  
&lt;br&gt;https://doi.org/10.1182/blood-2007-12-129262</mixed-citation></ref><ref id="hanspub.44144-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Fornoni, A., Sageshima, J., Wei, C., Merscher-Gomez, S., Aguillon-Prada, R., Jauregui, A.N., et al. (2011) Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis. Science Translational Medicine, 3, 85ra46.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.3002231</mixed-citation></ref><ref id="hanspub.44144-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, Y., Ikezumi, Y. and Saitoh, A. (2017) Rituximab Protects Podocytes and Exerts Anti-528 Proteinuric Effects in Rat Adriamycin-Induced Nephropathy Independent of B-Lymphocytes. Nephrology (Carlton), 22, 49-57.  
&lt;br&gt;https://doi.org/10.1111/nep.12737</mixed-citation></ref><ref id="hanspub.44144-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Iijima, K., et al. (2014) Rituximab for Childhood-Onset, Complicated, Frequently Relapsing Nephrotic Syndrome or Steroid-Dependent Nephrotic Syndrome: A Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. The Lancet, 384, 1273-1281. &lt;br&gt;https://doi.org/10.1016/S0140-6736(14)60541-9</mixed-citation></ref><ref id="hanspub.44144-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ruggenenti, P., et al. (2014) Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology, 25, 850-863. &lt;br&gt;https://doi.org/10.1681/ASN.2013030251</mixed-citation></ref><ref id="hanspub.44144-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Van Horebeek, I., et al. (2017) Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: Experience of a Tertiary Center and Review of the Literature. Acta Clinica Belgica, 72, 147-155.  
&lt;br&gt;https://doi.org/10.1080/17843286.2016.1208955</mixed-citation></ref><ref id="hanspub.44144-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Basu, B., et al. (2018) Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome. JAMA Pediatrics, 172, 757. &lt;br&gt;https://doi.org/10.1001/jamapediatrics.2018.1323</mixed-citation></ref><ref id="hanspub.44144-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Bagga, A., Moudgil, A. and Sinha, A. (2007) Rituximab in Patients with the Steroid-Resistant Nephrotic Syndrome. The New England Journal of Medicine, 356, 2751-2752. &lt;br&gt;https://doi.org/10.1056/NEJMc063706</mixed-citation></ref><ref id="hanspub.44144-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sinha, A., et al. (2015) Efficacy and Safety of Rituximab in Children with Difficult-to-Treat Nephrotic Syndrome. Nephrology Dialysis Transplantation, 30, 96-106. &lt;br&gt;https://doi.org/10.1093/ndt/gfu267</mixed-citation></ref><ref id="hanspub.44144-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Kamei, K., et al. (2014) Rituximab Treatment Combined with Methylprednisolone Pulse Therapy and Immunosuppressants for Childhood Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 29, 1181-1187.  
&lt;br&gt;https://doi.org/10.1007/s00467-014-2765-z</mixed-citation></ref><ref id="hanspub.44144-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hoseini, R., et al. (2018) Efficacy and Safety of Rituximab in Children with Steroid- and Cyclosporine-Resistant and Steroid- and Cyclosporine-Dependent Nephrotic Syndrome. Iranian Journal of Kidney Diseases, 12, 27-32.</mixed-citation></ref><ref id="hanspub.44144-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Suyama, K., et al. (2016) Rituximab and Low-Dose Cyclosporine Combination Therapy for Steroid-Resistant Focal Segmental Glomerulosclerosis. Pediatrics International, 58, 219-223. &lt;br&gt;https://doi.org/10.1111/ped.12804</mixed-citation></ref><ref id="hanspub.44144-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Prytuła, A., et al. (2010) Rituximab in Refractory Nephrotic Syndrome. Pediatric Nephrology, 25, 461-468.  
&lt;br&gt;https://doi.org/10.1007/s00467-009-1376-6</mixed-citation></ref><ref id="hanspub.44144-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sun, L., et al. (2014) Efficacy of Rituximab Therapy in Children with Refractory Nephrotic Syndrome: A Prospective Observational Study in Shanghai. World Journal of Pediatrics, 10, 59-63. &lt;br&gt;https://doi.org/10.1007/s12519-014-0453-5</mixed-citation></ref><ref id="hanspub.44144-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Bonanni, A., et al. (2018) Adverse Events Linked with the Use of Chimeric and Humanized Anti-CD20 Antibodies in Children with Idiopathic Nephrotic Syndrome. British Journal of Clinical Pharmacology, 84, 1238-1249.  
&lt;br&gt;https://doi.org/10.1111/bcp.13548</mixed-citation></ref><ref id="hanspub.44144-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Parmentier, C., et al. (2020) Immunoglobulin Serum Levels in Rituximab-Treated Patients with Steroid-Dependent Nephrotic Syndrome. Pediatric Nephrology, 35, 455-462. &lt;br&gt;https://doi.org/10.1007/s00467-019-04398-1</mixed-citation></ref><ref id="hanspub.44144-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Fujinaga, S., et al. (2019) Long-Term Outcomes after Early Treatment with Rituximab for Japanese Children with Cyclosporine- and Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 34, 353-357.  
&lt;br&gt;https://doi.org/10.1007/s00467-018-4145-6</mixed-citation></ref><ref id="hanspub.44144-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Sato, M., et al. (2013) Atypical Pneumocystis jiroveci Pneumonia with Multiple Nodular Granulomas after Rituximab for Refractory Nephrotic Syndrome. Pediatric Nephrology, 28, 145-149. &lt;br&gt;https://doi.org/10.1007/s00467-012-2286-6</mixed-citation></ref><ref id="hanspub.44144-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ardelean, D.S., et al. (2010) Severe Ulcerative Colitis after Rituximab Therapy. Pediatrics (Evanston), 126, e243.  
&lt;br&gt;https://doi.org/10.1542/peds.2009-3395</mixed-citation></ref><ref id="hanspub.44144-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Chaumais, M., et al. (2009) Fatal Pulmonary Fibrosis after Rituximab Administration. Pediatric Nephrology, 24, 1753-1755. &lt;br&gt;https://doi.org/10.1007/s00467-009-1195-9</mixed-citation></ref><ref id="hanspub.44144-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Grenda, R., Jarmużek, W., Rubik, J., Migdał, M. and Pronicki, M. (2015) Fatal Rituximab-Associated Lung Injury Syndrome in a Patient Treated with Rituximab for Recurrence of Post-Transplant Nephrotic Syndrome. Pediatric Transplantation, 19, E115-E120. &lt;br&gt;https://doi.org/10.1111/petr.12481</mixed-citation></ref></ref-list></back></article>